Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028 Rionero in Vulture (PZ), Italy.
Institute of Experimental Endocrinology and Oncology, National Research Council, 80131 Naples, Italy.
Int J Mol Sci. 2019 Jul 31;20(15):3736. doi: 10.3390/ijms20153736.
Despite the significant recent advances in clinical practice, gastric cancer (GC) represents a leading cause of cancer-related deaths in the world. In fact, occurrence of chemo-resistance still remains a daunting hindrance to effectiveness of the current approach to GC therapy. There is accumulating evidence that a plethora of cellular and molecular factors is implicated in drug-induced phenotypical switching of GC cells. Among them, epithelial-mesenchymal transition (EMT), autophagy, drug detoxification, DNA damage response and drug target alterations, have been reported as major determinants. Intriguingly, resistant GC phenotype may be the result of GC cell-induced tumor microenvironment (TME) remodeling, which is currently emerging as a key player in promoting drug resistance and overcoming cytotoxic effects of drugs. In this review, we discuss the possible mechanisms of drug resistance and their involvement in determining current GC therapies failure.
尽管近年来临床实践取得了重大进展,但胃癌(GC)仍是全球癌症相关死亡的主要原因。事实上,化疗耐药的发生仍然是当前 GC 治疗方法有效性的一个令人畏惧的障碍。有越来越多的证据表明,许多细胞和分子因素参与了 GC 细胞药物诱导表型转换。其中,上皮-间充质转化(EMT)、自噬、药物解毒、DNA 损伤反应和药物靶点改变被报道为主要决定因素。有趣的是,耐药 GC 表型可能是 GC 细胞诱导肿瘤微环境(TME)重塑的结果,目前 TME 重塑作为促进耐药和克服药物细胞毒性作用的关键因素而出现。在这篇综述中,我们讨论了耐药的可能机制及其在决定当前 GC 治疗失败中的作用。